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Introduction
Endothelial cells play a key role in regulating arterial health and vascular tone. These cells respond to increased blood flow and the resulting shear stress by producing factors that lead to arterial dilatation [flow-mediated dilatation (FMD)]. The endothelial response, including the transduction mechanisms and vasodilators produced, appears to be somewhat specific to the nature of the shearstress stimulus (Frangos et al. 1996; Mullen et al. 2001; Pyke & Tschakovsky, 2005 , 2007 Findlay et al. 2013) . However, our current understanding of human endothelial function has relied heavily on examining the FMD response to one particular shear-stress stimulus profile, i.e. the transient increase in conduit artery shear stress experienced upon the release of temporary limb occlusion [reactive hyperaemia (RH); Celermajer et al. 1992] .
There is evidence that fluctuation in oestrogen (17β-estradiol (E2)) throughout the menstrual cycle can influence brachial artery FMD stimulated by RH-induced increases in shear stress (RH-FMD), with several (Hashimoto et al. 1995; Kawano et al. 2001; Williams et al. 2001; Adkisson et al. 2010; Harris et al. 2012) but not all studies (Jochmann et al. 2009; Saxena et al. 2012; Rakobowchuk et al. 2013) reporting an augmented brachial artery RH-FMD response in the late follicular (LF; high-oestrogen) phase compared with the early follicular (EF; low-oestrogen) phase of the menstrual cycle. This impact of E2 on vascular endothelial function has been attributed, in part, to oestrogen-associated increases in the bioavailability of nitric oxide (NO), a vasodilator released by the endothelium in response to shear stress (Mendelsohn & Karas, 1999 Mendelsohn, 2002) .
In addition to the standard RH-FMD technique, FMD can be assessed in response to sustained increases in shear stress, and several studies have used handgrip exercise (HGEX) for this purpose (Pyke et al. 2008a; Wray et al. 2011; Findlay et al. 2013; Slattery et al. 2016) . Some of the few studies examining FMD in response to transient versus prolonged increases in shear stress have reported a similar impact of acute interventions and chronic conditions (Gaenzer et al. 2001; Ade et al. 2015) . For example, it has been shown that a 30 min exposure to elevated shear stress via hand warming results in an elevation in both subsequent RH-FMD (Tinken et al. 2009 ) and HGEX-FMD (Ade et al. 2015) . However, others have noted distinct impacts of mental stress, a short history of smoking, obesity, hypercholesterolaemia and type 1 diabetes on these FMD responses (Mullen et al. 2001; Bellien et al. 2010; Grzelak et al. 2010; Findlay et al. 2013; Szijgyarto et al. 2013; Slattery et al. 2016) , sometimes reporting a greater or exclusive impairment of FMD in response to a sustained increase in shear stress (Bellien et al. 2010; Findlay et al. 2013; Slattery et al. 2016) . Taken together, the evidence suggests that the impact of vasoactive stimuli on RH-FMD cannot be generalized to FMD stimulated by HGEX-induced increases in shear stress (HGEX-FMD) .
The distinct impact of various conditions and acute interventions on RH-versus HGEX-FMD may derive from the recruitment of distinct shear-stress transduction mechanisms. Although there is evidence that both FMD responses involve NO (Wray et al. 2011; Green et al. 2014) , the signalling pathways leading to vasodilator production may be specific to the shear-stress profile (Frangos et al. 1996) . This suggests that a more comprehensive understanding of endothelial function and the impact on endothelial function of various factors, including menstrual phase, may be derived from the assessment of FMD in response to multiple shear-stress stimuli. Characterizing the FMD response to exercise-induced increases in shear stress (e.g. HGEX-FMD) also provides physiologically relevant information regarding regulation of vascular tone during normal activity, and this may be functionally relevant for perfusion (Duffy et al. 1999; Patel et al. 2005; Heffernan et al. 2010; Vita & Hamburg, 2010) . The impact of menstrual phase on the conduit artery FMD response to exercise-induced increases in shear stress, including brachial artery HGEX-FMD, remains unknown.
Therefore, the purpose of this study was to determine whether HGEX-FMD fluctuates with the cyclical changes in oestrogen concentrations over two discrete phases (low and high oestrogen) of the menstrual cycle. Given the well-established interaction between oestrogen and NO, and evidence that NO is likely to play a role in HGEX-FMD (Wray et al. 2011) , it is hypothesized that HGEX-FMD will be higher in the high-oestrogen phase. Through investigation of the FMD response to a sustained shear-stress stimulus (HGEX-FMD), this study provides a more thorough characterization of the impact of oestrogen on endothelial function.
Methods

Ethical approval
The study protocol was approved by the Health Sciences Research Ethics Board at Queen's University (approval no. TRAQ# 6004461; Department code PHE-090-09), which conforms to the standards set by the Declaration of Helsinki (with the exception that this study was not registered in a database). Written informed consent was obtained on forms approved by this board prior to study participation.
Participants and screening visit
Twelve healthy, regularly menstruating, non-smoking, young women (19-27 years of age) recruited from Queen's University and the surrounding community participated in the study. Volunteers came to the laboratory for a Impact of menstrual phase on flow-mediated dilatation during exercise screening visit to assess their eligibility, which included completion of a medical screening questionnaire and blood pressure assessment (BpTRU BPM-100; BpTRU Medical Devices, Coquitlam, BC, Canada). Individuals reporting irregular menstrual cycles (<10 cycles per year) or the use of hormonal therapy were excluded. Additional exclusion criteria included the following: reporting a history of cardiovascular or metabolic disease, taking medications to treat cardiovascular risk factors and/or levels of physical activity that exceeded 3 h of structured sessions per week. Volunteers who were hypo-(<90/60 mmHg) or hypertensive (>140/90 mmHg) at the time of screening were also excluded. Volunteers were familiarized with the study protocol and screened to ensure that a clear image of the brachial artery and a strong blood velocity signal could be collected. A bout of HGEX was also performed to estimate the percentage of maximal voluntary contraction (%MVC) required to reach the shear-rate target for the HGEX-FMD testing (see full description in subsection: Brachial Artery Handgrip Exercise (HGEX-FMD)). Volunteers meeting the above criteria were asked to report their most recent menstrual period, which was used to predict the start of their upcoming menstrual cycle. If the menstrual cycle started as predicted, both experimental visits were scheduled to correspond to two discrete phases of the menstrual cycle. Participants were instructed to abstain from food for 6 h and to avoid alcohol, caffeine and exercise for 24 h before each experimental visit (Thijssen et al. 2011) . Prior to fasting, participants were instructed to consume the same meal before each visit.
Experimental design
Participants were required to complete two identical experimental visits (Fig. 1) . The two visits corresponded to the two phases of the menstrual cycle studied: (i) the low-oestrogen (early follicular, EF) phase; and (ii) the high-oestrogen (late follicular, LF) phase of the menstrual cycle. The duration between the start of two consecutive menstrual periods was considered one complete cycle. Day 1 of the menstrual cycle represents the first day of the menstrual period. The low-oestrogen (EF) experimental visit occurred within days 2-7 of the menstrual cycle. The high-oestrogen (LF) experimental visit occurred within days 13-14 of the menstrual cycle. Participants completed the same protocol during each visit.
Upon arrival at the laboratory, participants were instructed to lie supine for 30 min. During this rest period, a single venous blood sample was obtained to permit analysis of oestrogen concentrations. Owing to difficulties in obtaining the blood sample, oestrogen data are reported for 11 of the 12 participants. Samples were taken directly to the Kingston General Hospital core laboratory for same-day oestrogen analysis. Blood pressure was assessed at the end of the rest period, followed by two RH-and two HGEX-FMD trials (Fig. 1) . The order of trials on each day (i.e. whether RH-or HGEX-FMD trials were performed first) was counterbalanced between participants but remained consistent within participants across phases.
Experimental procedures
Heart rate and blood pressure. A three-lead ECG was used to obtain heart rate (HR), and this signal was recorded in the program LabChart (AD Instruments, Colorado Springs, CO, USA). Blood pressure was measured as the average of two recordings (BpTRU BPM-100; BpTRU Medical Devices) at the time point identified in Fig. 1 
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Brachial artery diameter measurements. Brachial artery diameter was obtained using two-dimensional ultrasound in B-mode (12 MHz; Vivid i2; GE Medical Systems, Mississauga, Canada). Data were collected with an insonation angle of 68 deg for reasons previously described (Pyke et al. 2008a) . Ultrasound images were recorded with a VGA-to-USB frame grabber (Epiphan Systems Inc., Ottawa, Canada) and saved as .avi files on a separate computer using commercially available software (Camtasia Studio; TechSmith, Okemos, MI, USA) as previously described (Jazuli & Pyke, 2011) .
Brachial artery blood velocity measurements. Brachial artery blood velocity was obtained using Doppler ultrasound operating at 4 MHz (Vivid i2; GE Medical Systems). The Doppler shift frequency spectrum was analysed using a Multigon 500P TCD spectral analyser (Multigon Industries, Yonkers, NY, USA) to determine the mean blood velocity. The resulting voltage output from the Multigon was continuously recorded (LabChart; AD Instruments) for subsequent analysis as previously described (Jazuli & Pyke, 2011) .
Brachial artery reactive hyperaemia (RH-FMD).
Two trials of RH-FMD were performed during each experimental visit ( Fig. 1 ). An occlusion cuff was placed on the participant's left forearm at the antecubital fossa, which was distal to the location of the brachial artery ultrasound probe. Baseline brachial artery diameter and blood velocity were recorded for 1 min before cuff inflation to 250 mmHg for 5 min. Brachial artery diameter and blood velocity were recorded 1 min before and 3 min after cuff release. Each FMD test was separated by a minimum of 10 min or until the diameter returned to baseline between trials.
Brachial artery handgrip exercise (HGEX-FMD).
Two trials of HGEX-FMD were performed during each experimental visit ( Fig. 1) . During each experimental visit participants were asked to perform two maximal isometric voluntary contractions (MVCs) using a handgrip dynamometer. Participants started exercising at the intensity (%MVC) estimated in the screening visit as the intensity required to elicit the target shear rate of 75 s −1 . This shear rate has been shown previously to elicit a significant HGEX-FMD response (Findlay et al. 2013) . Shear rate is an estimate of shear stress (without blood viscosity) and was calculated as: mean blood velocity/vessel diameter. To achieve the target shear rate, the blood velocity required was calculated as: required velocity = 75 s −1 × brachial artery diameter. For this calculation, the brachial artery diameter for each subject was estimated using manual placement of callipers on the ultrasound image before each trial. For both trials, participants were coached through minor variations in intensity (%MVC) to maintain the required velocity, and therefore the target shear rate (Pyke et al. 2008b; Jazuli & Pyke, 2011) .
Brachial artery diameter and blood velocity were recorded for 1 min at baseline and for 6 min of HGEX. Participants performed contractions at the %MVC necessary to reach the target shear rate in time with a 1 s contraction/5 s relaxation duty cycle metronome.
Data analysis
Oestrogen analysis. Concentrations of E2 were determined using the Beckman Coulter UniCel DxI 800 Access Immunoassay System at the Kingston General Hospital Laboratory.
Mean arterial pressure (MAP) and HR. Resting MAP was calculated from systolic (SBP) and diastolic blood pressure (DBP) output from the BPTru using the following equation: MAP = (SBP + 2DBP)/3. Resting HR was taken as a 1 min average collected during the rest period.
Brachial artery blood velocity. Three second average time bins were analysed offline using data acquisition software (LabChart; AD Instruments), as described by Pyke et al. (2008a) .
Brachial artery diameter. Vessel diameter was analysed using automated edge-detection software (Encorder FMD and Bloodflow v3.0.3; Reed Electronics, Perth, Australia) as previously described (Jazuli & Pyke, 2011) . The diameter data were compiled in 3 s time bins for calculation of shear rate. The HGEX-FMD diameters were then compiled into 1 min averages.
Shear rate. Shear rate was calculated using the expression: mean blood velocity/brachial artery diameter (Gnasso et al. 2001) . For the RH-FMD trials, the shear-rate stimulus was quantified as the shear rate area under the curve (SR AUC) in the first 30 s after cuff release. For the HGEX-FMD, the shear-rate stimulus was quantified as both the average of the last 5 min of exercise (steady-state period) and the shear rate during each minute of exercise. In two participants, RH velocity signals were lost in both trials in one or more phases studied and, as such, the average shear rate (SR AUC) was determined from the remaining 10 participants with complete data.
Flow-mediated dilatation. A single, blinded investigator (K.A.D.) analysed all images. The RH-FMD is reported as both absolute change and percentage change (%FMD) in diameter. The percentage RH-FMD was calculated as the percentage difference in arterial diameter from baseline to the peak 3 s average diameter time bin after cuff release; absolute FMD was reported as the difference (in Impact of menstrual phase on flow-mediated dilatation during exercise millimetres) between these same values. For HGEX-FMD, the percentage change was calculated as the percentage difference in diameter from baseline to the peak 1 min average diameter during exercise; absolute FMD was reported as the difference (in millimetres) between these same values. In addition, HGEX-FMD was calculated as the difference in diameter from baseline to the diameter recorded during each minute (minute 1-6) of exercise. The two like trials in each phase were averaged to provide one response for each test. Single trials were used to represent FMD in the event that one trial had substantially superior image quality (single trial used: RH-FMD, one participant in EF and three participants in LF phase; HGEX-FMD, three participants in EF and two participants in LF phase). Changes in FMD across phases were calculated as LF minus EF, such that if FMD was higher in the LF phase, the change ( ) would appear as a positive number.
Statistical analysis. All statistical analysis was performed using SigmaPlot 11 software (Systat Software Inc., San Jose, CA, USA) or IBM SPSS (SPSS Inc., Chicago, IL, USA). All values are expressed as the mean ± (SD). Statistical significance was set at P < 0.05. Student's paired t tests were used to assess the impact of menstrual phase on E2, HR, MAP, peak HGEX-FMD, RH-FMD, the RH-FMD SR AUC and the steady-state shear rate during HGEX. A Wilcoxon signed rank test was performed if the test for normal distribution failed. The FMD analysis was repeated with SR AUC (RH-FMD) and baseline diameter (RH-FMD and HGEX-FMD) as a covariate (SPSS linear mixed model analysis). Two-way repeated-measures ANOVAs with factors phase (low and high oestrogen) and time (minutes 1-6 of exercise) were used to examine the time course of HGEX-FMD and the shear rate stimulus during HGEX.
Linear regression analysis was used to assess associations between the following: (i) E2 and FMD in each phase and between the phase change in E2 and phase change in FMD; (ii) the SR AUC and RH-FMD in each phase, as well as the phase change in SR AUC and the phase change in RH-FMD; and (iii) the phase change in RH-FMD and phase change in HGEX-FMD.
Three oestrogen values in the low-oestrogen (EF) phase were below the detectable range of the assay (27 pg ml −1 ). Therefore, multiple imputation (10 imputations) was performed to predict values between 0.1 and 27 pg ml −1 to estimate the three missing values. Student's paired t tests comparing the EF and LF phase E2 were performed for each imputation, and the average of the 10 P values is reported. Likewise, regression analysis that included E2 was performed for each imputation, and the average of the 10 P values and r 2 values is reported (Uh et al. 2008) . The reported mean EF E2 in Table 1 was calculated by replacing each missing value with the mean of its 10 imputed values. 
Results
Subject characteristics
Twelve participants, with a mean age of 21 ± 2 years and body mass index of 22.2 ± 1.9 kg m −2 , completed this study during two phases of the menstrual cycle. The average cycle duration was 30 ± 3 days.
Oestrogen
Mean E2 data are presented in Table 1 and individual E2 data in Fig. 2 . Plasma E2 concentrations were greater during the LF phase when compared with the EF phase (P = 0.003).
Mean arterial pressure and HR
No significant differences in baseline MAP or HR were observed across the two phases of the menstrual cycle (Table 1) .
Shear rate RH-FMD test.
The baseline shear rate and the shear-rate stimulus (AUC to 30 s after cuff deflation) were not significantly different between phases (Table 2 and Fig. 3A) . 3.0 ± 0.5 3.1 ± 0.4 0.163
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Values are means ± SD. Abbreviations are as for Table 2 .
HGEX-FMD test. There were no significant differences in baseline or steady-state (last 5 min of exercise) shear rate between phases (Table 2 and Fig. 3C ). There were also no phase differences in the time course of the shear-rate increase (time P = 0.01, phase P = 0.504, time-by-phase interaction P = 0.825; Fig. 3E ). The %MVC performed to achieve this shear rate was not significantly different between phases (Table 2) .
Baseline diameter and FMD
RH-FMD.
There were no significant differences in baseline diameter (Table 3) , %RH-FMD (P = 0.071; Fig. 3B ) or time-to-peak RH-FMD between phases (Table 3) . Absolute RH-FMD was also not significantly different between phases (P = 0.233; Wilcoxon signed rank test). Likewise, no significant difference in %RH-FMD or absolute RH-FMD was observed between phases when baseline diameter was added as a covariate (P = 0.151 and P = 0.442, respectively). In each phase, the SR stimulus was related to the FMD response (EF, r 2 = 0.600, P = 0.008; and LF, r 2 = 0.647, P = 0.005). Across phases there was a borderline significant relationship between SR AUC and %FMD (r 2 = 0.400, P = 0.05). However, there were still no significant phase differences in %RH-FMD or absolute RH-FMD when SR AUC was added as a covariate (P = 0.392 and P = 0.379, respectively). No significant relationships between oestrogen and RH-FMD were found ( E2 versus %RH-FMD; Fig. 4A ).
HGEX-FMD.
There were no significant differences in baseline diameter (Table 3) or peak %HGEX-FMD (P = 0.601; Fig. 3D ) between phases. Peak absolute HGEX-FMD also did not differ between phases (P = 0.857). Likewise, no significant phase differences in peak %HGEX-FMD or absolute HGEX-FMD were observed when baseline diameter was added as a covariate (P = 0.559 and P = 0.527). Minute-by-minute analysis revealed the expected main effect of time (P < 0.001) and no effect of phase (P = 0.854) or time-by-phase interaction for %HGEX-FMD (P = 0.304; Fig. 3F ). Absolute HGEX-FMD was also not significantly different between phases when analysed over time (P = 0.908). No significant relationships between oestrogen and HGEX-FMD were found ( E2 versus %HGEX-FMD; Fig. 4B ). There was also no correlation between the change in %RH-FMD 
Discussion
This study provided the first investigation of the impact of menstrual phase on FMD in response to a sustained shear-stress stimulus and is the first to report the time course of dilatation. The primary finding was that although E2 was significantly higher in the LF phase, neither the magnitude nor the time course of HGEX-FMD differed between phases. In addition, we observed no phase differences in RH-FMD. These findings indicate that in contrast to several previous studies and what has become an established understanding (Thijssen et al. 2011) , endothelial function may not universally fluctuate in correspondence with cyclic oestrogen changes in healthy, premenopausal women. Understanding the mechanisms that underlie the variability in FMD responses to cyclic fluctuation in E2 is important because they may have vascular health and perfusion implications (Kawano et al. 2001) .
Impact of menstrual cycle phase on HGEX-FMD
This is the first study to investigate the impact of menstrual phase on FMD in response to a sustained shear-stress stimulus (HGEX-FMD). As previously stated, no significant difference in HGEX-FMD was observed between the early and late follicular phases of the menstrual cycle. This suggests that during physical activity, endothelial responses to shear stress are not enhanced in the high-oestrogen phase. With the observed variability, we had a power of 0.8 to detect a 1.4% difference in HGEX-FMD between phases (i.e. 4 versus 5.4% FMD). For perspective, although not all RH-FMD studies have detected phase differences (Jochmann et al. 2009; Saxena et al. 2012; Rakobowchuk et al. 2013) , studies that are frequently cited in support of an effect of the menstrual cycle on RH-FMD have reported a range of phase differences from ß1 to 9% (average 4.7%; Hashimoto et al. 1995; Kawano et al. 1996; Williams et al. 2001; Adkisson et al. 2010; Harris et al. 2012) .
In contrast to RH, HGEX more gradually increases blood flow and results in a controlled and sustained brachial artery shear-stress stimulus. We were successful in creating the same stimulus magnitude across phases, with little within-subject variability ( Fig. 3C and E) . Recently, several studies have shown that RH-and HGEX-stimulated FMD provide distinct information regarding endothelial function (Padilla et al. 2006; Grzelak et al. 2010; Findlay et al. 2013; Szijgyarto et al. 2013; Slattery et al. 2016) . These findings have been attributed to potential mechanistic differences in the FMD response stimulated by transient versus sustained shear-stress stimuli (Frangos et al. 1996; Bellien et al. 2006; Pyke et al. 2008a) . Given the evidence demonstrating a degree of NO dependence for HGEX-FMD (Wray et al. 2011) , it was expected that the HGEX-FMD response would demonstrate some sensitivity to variations in E2 across the menstrual cycle. However, the finding that the magnitude of HGEX-FMD did not parallel changes in oestrogen lends support to the conclusion that the normal range of oestrogen fluctuation between the early and late follicular phases does not uniformly impact endothelial function. There is evidence that the degree to which RH-FMD is NO dependent varies between individuals (Pyke et al. 2010; Parker et al. 2011; Wray et al. 2013) , and this could also be true of HGEX-FMD. If this sample contained predominantly participants in whom neither RH nor HGEX-FMD was NO dependent that could explain the overall lack of observed phase differences. It is possible that . Relationships between menstrual phase differences in oestrogen and flow-mediated dilation A, change ( ) in oestrogen (E2) versus %RH-FMD from low-to high-oestrogen phase (r 2 = 0.04, P = 0.53). B, oestrogen (E2) versus %HGEX-FMD from low-to high-oestrogen phase (r 2 = 0.09, P = 0.37). For the three participants with EF E2 values below the range of the assay, the E2 shown graphically was calculated using the average of their EF values generated in multiple imputation analysis (average of 10 imputations). Regression analysis was performed using E2 values calculated for each of the 10 imputations. The reported r 2 and P values are the averages from these 10 regressions. Abbreviations: E2, 17β-estradiol; HGEX, handgrip exercise; and RH, reactive hyperaemia.
HGEX-FMD might be consistently impervious to changes across the menstrual cycle, even in groups where enhanced LF RH-FMD is observed. To determine that, the phase comparison of RH and HGEX-FMD must be repeated in the presence of enhanced LF RH-FMD.
Impact of menstrual cycle phase on RH-FMD
A number of previous studies have reported an augmented RH-FMD in the high-oestrogen phase of the menstrual cycle in healthy, regularly cycling, premenopausal women (Hashimoto et al. 1995; English et al. 1998; Kawano et al. 2001; Williams et al. 2001; Adkisson et al. 2010; Harris et al. 2012) . These findings have influenced methodological guidelines for FMD assessment, which recommend that women should be tested in the first 7 days of the menstrual cycle (EF phase; Thijssen et al. 2011) . In these studies, oestrogen-mediated increases in NO bioavailability have been cited as a possible mechanism driving improvements in RH-FMD. For example, Adkisson et al. (2010) , demonstrated augmented RH-FMD and plasma nitrate and nitrite (NOx) concentrations in the high-oestrogen phase of the menstrual cycle compared with all other phases studied. Although all of these studies found an effect at the group level, examination of the individual data presented by Williams et al. (2001) shows that that several participants had little change in RH-FMD between the EF and LF phases, and three of 15 declined from the EF to LF phase. Furthermore, the study conducted by English et al. (1998) showed varying degrees of decline in RH-FMD from the follicular phase (low oestrogen) to mid-cycle (high oestrogen) in seven of 20 participants. However, it must be noted that English et al. (1998) used cuff occlusion proximal to the site of FMD measurement, and this has been shown to lessen NO dependence of RH-FMD (Doshi et al. 2001) .
In agreement with a smaller number of recent, but less frequently recognized studies (Jochmann et al. 2009; Saxena et al. 2012; Rakobowchuk et al. 2013; Luca et al. 2016) , the present study demonstrated no significant differences in RH-FMD across two discrete phases of the menstrual cycle. Participant characteristics and the RH-FMD protocol used in the present study and others finding an impact of menstrual phase on RH-FMD are very similar, and therefore do not appear to be the root of the discrepant findings. With the observed variability, we had a power of 0.8 to detect an RH-FMD phase difference of 2.4%. As mentioned above, the range reported by previous studies that have detected a significant effect is ß1-9% (Hashimoto et al. 1995; Kawano et al. 1996; Williams et al. 2001; Adkisson et al. 2010; Harris et al. 2012) . Combined with the observation that FMD in the high-oestrogen phase was, in fact, smaller than in the low-oestrogen phase in 10 of the 12 participants (average ß1.5% lower in LF versus EF; Fig. 3B ) and the agreement between the present findings and several others that have not found evidence of an effect of phase, it seems unlikely that the lack of phase difference is explained by insufficient power.
The mean E2 concentrations reported in the high-and low-oestrogen phases of the menstrual cycle in studies that did and did not find phase differences in FMD, including the present study, are comparable (Hashimoto et al. 1995; Kawano et al. 2001; Williams et al. 2001; Adkisson et al. 2010; Harris et al. 2012; Saxena et al. 2012; Rakobowchuk et al. 2013) . Interestingly, the mean magnitude of change in E2 between phases in the present study is greater than in three of the more widely cited studies showing higher RH-FMD in the high-oestrogen phase (mean E2: present study 128 pg ml −1 , compared with 77, ß80 and 119 pg ml −1 , respectively; Williams et al. 2001; Adkisson et al. 2010; Harris et al. 2012) . Although there was considerable individual variability in the magnitude of the LF E2 in the present study (Fig. 2) , as shown in Fig. 4 , the magnitude of the E2 change did not relate to phase changes in FMD. Thus, it seems unlikely that an inadequate magnitude of change in E2 across phases explains the observed absence of a phase effect on RH-FMD. However, given the potential for exaggerated error when comparing change scores, it is possible that oestrogen could still be influencing the FMD response.
As mentioned above, studies have demonstrated that RH-FMD is (Joannides et al. 1995; Mullen et al. 2001; Green et al. 2014) and is not (Pyke et al. 2010; Wray et al. 2013 ) dependent on NO, and the existence of a phenotype wherein low NO bioavailability can be compensated by upregulation of other vasodilators has been suggested as a possible explanation (Pyke et al. 2010) . Predominant phenotype differences between studies could contribute to differences in the impact of phase (Pyke et al. 2010) . It is possible, in contrast to previous studies where phase differences in RH-FMD were observed, that participants in the present study were able to compensate for low NO bioavailability in the low-oestrogen phase by upregulating other vasodilators. This is speculative, and the reasons for inter-individual/inter-study variability in susceptibility to menstrual cycle fluctuation in RH-FMD require further study. This could have clinical significance if susceptibility to menstrual cycle fluctuations in E2 relates to susceptibility to changes in endothelial function after menopause.
Examination of Fig. 3B indicates that there was considerable inter-individual variability in RH-FMD and how it changed across phases (in the absence of a systematic increase in the LF phase). Reactive hyperaemia is an inherently variable stimulus, and there was a strong relationship between the SR AUC and RH-FMD in each phase, and the relationship between the change in shear rate and change in FMD across phases achieved borderline significance. This indicates that the stimulus variability made an important contribution to the RH-FMD response K. A. D'Urzo and others variability. However, controlling for the stimulus, via its addition as a covariate, did not reveal any phase differences in RH-FMD.
Limitations
In this study, FMD was assessed only at two discrete phases of the menstrual cycle to examine the impact of oestrogen fluctuation on endothelial function, a methodology that was informed by previous studies indicating the most pronounced impact of menstrual phase on FMD between the early and late follicular phases. Peak E2 varies considerably and occurs at different time points throughout the menstrual cycle in different individuals. Therefore, scheduling the LF visit on day 13-14 based on self-reported documentation of menstrual cycle timing might have resulted in a failure to capture the peak cycle oestrogen concentration consistently. Additional assessments of FMD within the follicular phase might have allowed better alignment between individual peak E2 concentrations and FMD assessment. However, given the comparable mean E2 values reported in the present study and others that found higher RH-FMD in the LF phase, and the observed lack of association between E2 and RH-FMD between phases, it seems unlikely that potential misalignment between the LF visit and peak E2 fully accounts for conflicting RH-FMD results between studies.
There is evidence suggesting that elevations in progesterone seen during the luteal phase of the menstrual cycle might also impact endothelial function. For example, with a similar concentration of oestrogen and higher progesterone than the LF phase, a blunted RH-FMD in the luteal phase versus the menstrual and LF phases has been observed (Williams et al. 2001) , although this finding is not universal (Harris et al. 2012) . In addition, when oestrogen and progesterone are administered exogenously, progesterone can antagonize the beneficial effects of oestrogen (Miner et al. 2011 ). Therefore, it is possible that the variability in FMD responses observed in the present study might relate to the effects of progesterone. However, there is evidence to suggest that it is unlikely that progesterone was elevated during our LF measurement. Studies reporting a similar cycle length and FMD assessment at ßdays 12-13 noted that progesterone was not elevated (serum progesterone, Williams et al. 2001; salivary progesterone, Harris et al. 2012 ).
An additional limitation is that we were unable to test the NO dependence of FMD. This would have allowed for an investigation of the interaction between NO dependence and the impact of menstrual phase on FMD. This awaits further study, but does not alter the primary conclusion that HGEX-FMD is not universally impacted by menstrual phase in healthy young women.
Conclusions
This study was the first to evaluate the impact of menstrual phase on HGEX-FMD and demonstrated no significant differences between phases. Furthermore, in contrast to several (but not all) other studies and the established understanding (Thijssen et al. 2011) , RH-FMD was not significantly different between phases of the menstrual cycle. These findings indicate that menstrual phase fluctuation in E2 does not universally influence FMD responses to transient (RH) or sustained (HGEX) shear-stress stimuli in young, healthy, premenopausal women. This suggests that cyclic fluctuation in endothelial function is not universally present. Further investigations are necessary to improve our understanding of the factors that underlie variability in the impact of menstrual phase on both transient and sustained FMD responses.
